Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study

Affiliations

• ¹ Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.
• ² A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.
• ³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
• ⁴ Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
• ⁵ Section of Dermatology, Department of Medicine, University of Brescia, Brescia, Italy.
• ⁶ Dermatology Unit, Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
• ⁷ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.